GlobeVerge
Home / business
MARKETS
AstraZeneca shares plunge over talks with US cancer drug firm on $400bn merger
GlobeVerge has tracked this story since 10h ago.
Bristol Myers Squibb tie-up would create world’s fourth largest drugmaker but analysts question rationale for deal More than £15bn was wiped off the value of Britain’s biggest drugmaker, AstraZeneca, on Monday after a report that it was in discussions to take over its US rival Bristol Myers Squibb i
Steady / neutral66%
PositivePossible support for stability, investment or market confidence
RiskInflation, volatility, borrowing costs or weaker growth
More in Finance
GlobeVerge Signal: A transparent, keyword-based read on this story's tone and stakes—not financial, political or safety advice. The summary above is the original publisher's excerpt, not AI-generated or rewritten by GlobeVerge. Open the original source link before acting on any story.